0001348911false00013489112023-12-072023-12-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 07, 2023

 

 

KALVISTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-36830	20-0915291
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
55 Cambridge Parkway Suite 901E
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 999-0075

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		KALV		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

Item 2.02 Results of Operations and Financial Condition.

On December 7, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended October 31, 2023. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit Number		Description
99.1		Press release dated December 7, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			KALVISTA PHARMACEUTICALS, INC.
Date:	December 7, 2023	By:	/s/ Benjamin L. Palleiko
			Benjamin L. Palleiko President, Chief Business Officer and Chief Financial Officer (Principal Financial and Accounting Officer)

 

---

Exhibit 99.1

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

 

 

Cambridge, MA and Salisbury, England, December 7, 2023 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.

“We are in the process of completing the KONFIDENT trial and we look forward to advancing sebetralstat for a NDA submission in the first half of 2024,” said Andrew Crockett, Chief Executive Officer of KalVista. “As we plan on several regulatory filings in the coming year, we are also continuing to build out our commercial organization in order to support a rapid launch upon FDA approval.”

Second Fiscal Quarter and Recent Business Highlights:

Second Fiscal Quarter Financial Results:

Revenue: No revenue was recognized for the three months ended October 31, 2023, or October 31, 2022.

R&D Expenses: Research and development expenses were $19.1 million for the three months ended October 31, 2023, compared to $18.1 million for the same period in the prior fiscal year. The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials.

---

Exhibit 99.1

G&A Expenses: General and administrative expenses were $10.7 million for the three months ended October 31, 2023, compared to $7.8 million for the same period in the prior fiscal year. The increase in G&A expenses was primarily due to increases in employee-related expenses, commercial strategy and supply chain expenses.

Net Loss: Net loss was $27.7 million, or $(0.80) per weighted average basic and diluted share, for the three months ended October 31, 2023, compared to net loss of $22.3 million, or $(0.90) per weighted average basic and diluted share for the same period in the prior fiscal year. The increase in net loss primarily resulted from the increase in operating expenses, primarily research and development.

Cash Position: Cash, cash equivalents and marketable securities were $103.2 million as of October 31, 2023, compared to $149.4 million as of April 30, 2023. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE and anticipates providing data from the phase 3 KONFIDENT clinical trial in early 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

 

For more information about KalVista, please visit www.kalvista.com.

 

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

 

Forward-Looking Statements

 

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that

---

Exhibit 99.1

may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Contact:

KalVista Pharmaceuticals, Inc.

Jarrod Aldom

Vice President, Corporate Communications

(201) 705-0254

jarrod.aldom@kalvista.com

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Exhibit 99.1

KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
	October 31,				April 30,
	2023				2023
Assets
Current assets:
Cash and cash equivalents	$	57,666			$	56,238
Marketable securities		45,506				93,137
Research and development tax credit receivable		19,976				16,568
Prepaid expenses and other current assets		5,458				6,383
Total current assets		128,606				172,326
Property and equipment, net		2,502				2,948
Right of use assets		7,298				7,822
Other assets		337				106
Total assets	$	138,743			$	183,202
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	4,896			$	4,817
Accrued expenses		11,707				9,128
Lease liability - current portion		1,148				1,087
Total current liabilities		17,751				15,032
Long-term liabilities:
Lease liability - net of current portion		6,546				7,145
Total long-term liabilities		6,546				7,145
Stockholders’ equity:
Common stock, $0.001 par value		34				34
Additional paid-in capital		513,926				507,133
Accumulated deficit		(396,049	)			(343,082	)
Accumulated other comprehensive loss		(3,465	)			(3,060	)
Total stockholders’ equity		114,446				161,025
Total liabilities and stockholders' equity	$	138,743			$	183,202

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Exhibit 99.1

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)
	Three Months Ended								Six Months Ended
	October 31,								October 31,
	2023				2022				2023				2022
Revenue	$	—			$	—			$	—			$	—
Operating expenses:
Research and development		19,089				18,077				38,396				36,262
General and administrative		10,657				7,806				20,443				15,936
Total operating expenses		29,746				25,883				58,839				52,198
Operating loss		(29,746	)			(25,883	)			(58,839	)			(52,198	)
Other income:
Interest income		776				449				1,699				691
Foreign currency exchange rate (loss) gain		(1,299	)			(317	)			(843	)			(834	)
Other income		2,619				3,494				5,016				7,042
Total other income		2,096				3,626				5,872				6,899
Net loss	$	(27,650	)		$	(22,257	)		$	(52,967	)		$	(45,299	)
Net loss per share, basic and diluted	$	(0.80	)		$	(0.90	)		$	(1.54	)		$	(1.84	)
Weighted average common shares outstanding, basic and diluted		34,565,955				24,595,039				34,490,090				24,576,327

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Exhibit 99.1

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
	Six Months Ended
	October 31,
	2023				2022
Cash flows from operating activities
Net loss	$	(52,967	)		$	(45,299	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		390				331
Stock-based compensation expense		6,461				5,148
Realized loss (gain) from sale of marketable securities		(909	)			85
Non-cash operating lease expense		(13	)			42
Amortization of premium on marketable securities		83				678
Foreign currency exchange loss (gain)		811				(739	)
Changes in operating assets and liabilities:
Research and development tax credit receivable		(4,109	)			(7,137	)
Prepaid expenses and other current assets		761				3,650
Accounts payable		163				(81	)
Accrued expenses		2,774				(14	)
Net cash used in operating activities		(46,555	)			(43,336	)
Cash flows from investing activities
Purchases of marketable securities		(29,537	)			(10,102	)
Sales and maturities of marketable securities		77,917				61,356
Acquisition of property and equipment		(8	)			(1,112	)
Website development costs		(203	)			—
Net cash provided by investing activities		48,169				50,142
Cash flows from financing activities
Issuance of common stock from equity incentive plans		332				336
Net cash provided by financing activities		332				336
Effect of exchange rate changes on cash and cash equivalents		(518	)			711
Net (decrease) increase in cash and cash equivalents		1,428				7,853
Cash and cash equivalents at beginning of period		56,238				30,732
Cash and cash equivalents at end of period	$	57,666			$	38,585

 

---